| Overview |
| bsm-61534r-apc-cy5 |
| PDCD4 Recombinant Monoclonal Antibody, APC-Cy5 Conjugated |
| WB, FCM, IF(ICC) |
| Human, Mouse |
| Specifications |
| APC-Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human PDCD4 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 27250 |
| Q53EL6 |
| Cytoplasm, Nucleus |
| Death up-regulated gene protein; Dug; H731; Ma3; Neoplastic transformation inhibitor; Nuclear antigen H731; Pdcd4; Programmed cell death protein 4; Tis. |
| Inhibits translation initiation and cap-dependent translation. May excert its function by hindering the interaction between EIF4A1 and EIF4G. Inhibits the helicase activity of EIF4A. Modulates the activation of JUN kinase. Down-regulates the expression of MAP4K1, thus inhibiting events important in driving invasion, namely, MAPK85 activation and consequent JUN-dependent transcription. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz